Mark J. Anderton
The Francis Crick Institute(GB)
Publications by Year
Research Areas
Computational Drug Discovery Methods, Synthesis and biological activity, Lung Cancer Treatments and Mutations, Cancer, Hypoxia, and Metabolism, Colorectal Cancer Treatments and Studies
Most-Cited Works
- → Discovery of a Potent and Selective EGFR Inhibitor (AZD9291) of Both Sensitizing and T790M Resistance Mutations That Spares the Wild Type Form of the Receptor(2014)591 cited
- → Impact of a five-dimensional framework on R&D productivity at AstraZeneca(2018)413 cited
- → Induction of Heart Valve Lesions by Small-Molecule ALK5 Inhibitors(2011)283 cited
- → Structure- and Reactivity-Based Development of Covalent Inhibitors of the Activating and Gatekeeper Mutant Forms of the Epidermal Growth Factor Receptor (EGFR)(2013)258 cited
- → Pharmacokinetics and Tissue Disposition of Indole-3-carbinol and Its Acid Condensation Products after Oral Administration to Mice(2004)217 cited
- → A Kainate Receptor Linked to Nitric Oxide Synthesis from Arginine(1989)200 cited
- → PHYSIOLOGICAL MODELING OF FORMULATED AND CRYSTALLINE 3,3′-DIINDOLYLMETHANE PHARMACOKINETICS FOLLOWING ORAL ADMINISTRATION IN MICE(2004)123 cited
- → Discovery of a Potent and Selective Oral Inhibitor of ERK1/2 (AZD0364) That Is Efficacious in Both Monotherapy and Combination Therapy in Models of Nonsmall Cell Lung Cancer (NSCLC)(2019)77 cited
- → Muscarine enhances soluble amyloid precursor protein secretion in human neuroblastoma SH-SY5Y by a pathway dependent on protein kinase Cα, src-tyrosine kinase and extracellular signal-regulated kinase but not phospholipase C(2002)52 cited
- → Liquid chromatographic assay for the simultaneous determination of indole-3-carbinol and its acid condensation products in plasma(2003)52 cited